Synaptive Medical has announced US Food and Drug Administration (FDA) registration of its next-generation robotic exoscope, Modus X.
Modus X, which is the fourth generation of Synaptive’s robotic exoscope, features redesigned 4K 3D optics, 27x magnification, automated image focus, voice guidance and more. The platform also enables fluorescence-guided surgery to improve oncological tissue differentiation in real-time, say Synaptive.
In addition, the flexible design of Modus X allows for field upgrades of Modus V, Synaptive’s third generation exoscope, currently installed in 80 hospitals worldwide.
Cameron Piron, president and co-founder of Synaptive Medical, said: “We anticipate these enhanced visualisation capabilities will enable surgeons to perform even more effective and precise interventions to the benefit of their patients. Through years of interdisciplinary collaboration with our clinical partners, we have arrived at this ultimate platform that pushes the boundaries of surgical visualisation.”